3'-Methoxy-4'-nitroflavone
3'-Methoxy-4'-nitroflavone (MNF) is a specific aryl hydrocarbon receptor (AhR) antagonist. 3'-Methoxy-4'-nitroflavone activates AhR by inhibiting CYP1, the metabolic enzyme of the endogenous ligand FICZ (HY-12451), leading to the accumulation of FICZ. 3'-Methoxy-4'-nitroflavone reverses the anti-apoptotic effect of TCDD, attenuates the activation of Akt and Erk1/2 kinases and the expression of TGFα induced by TCDD. 3'-Methoxy-4'-nitroflavone can be used in research related to breast tumor promotion, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease.
For research use only. We do not sell to patients.
- CAS No.: 145370-39-4
- Formula: C16H11NO5
- Molecular Weight:297.26
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
3'-Methoxy-4'-nitroflavone (0.1-1000 nM; 24 h) inhibits TCDD-dependent DRE-driven luciferase activity in MCF-10A cells at concentrations as low as 10 nM[1].
3'-Methoxy-4'-nitroflavone (0.1-1000 nM; 3 days) reverses the TCDD-dependent inhibition of apoptosis in MCF-10A cells, with significant effects observed at concentrations of 100 nM and 1000 nM[1].
3'-Methoxy-4'-nitroflavone (0.1-1000 nM; 6 h) reduces the phosphorylation level of Akt in MCF-10A cells, with significant inhibition observed at 1 nM and complete inhibition achieved at 100 nM[1].
3'-Methoxy-4'-nitroflavone (0.1-1000 nM; 6 h) reverses TCDD-mediated Erk1,2 phosphorylation in MCF-10A cells at concentrations of 10 nM and above, and when acting alone, its 1 nM concentration enhances basal Erk1,2 activation[1].
3'-Methoxy-4'-nitroflavone (0.1-100 nM; 6 h) completely abolishes TCDD-dependent TGFα mRNA expression in MCF-10A cells at concentrations as low as 1 nM[1].
3'-Methoxy-4'-nitroflavone (0.5-2.5 μM) potently inhibits the basal ethoxyresorufin O-deethylase activity of human recombinant CYP1A1[2].
3'-Methoxy-4'-nitroflavone (0.05-2.5 μM; 1.5-20 h) inhibits 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced ethoxyresorufin O-deethylase activity in HaCaT cells in a dose-dependent manner in vitro[2].
3'-Methoxy-4'-nitroflavone (0.05-2.5 μM; 1.5-48 h) first inhibits then enhances FICZ-dependent CYP1A1 mRNA expression and ethoxyresorufin O-deethylase activity in HaCaT cells, with a significant enhancing effect observable upon prolonged incubation[2].
3'-Methoxy-4'-nitroflavone (0.05-2.5 μM; 0-40 h) induces aryl hydrocarbon receptor-dependent ethoxyresorufin O-deethylase activity in HaCaT cells, and this effect depends on endogenous FICZ in the culture medium[2].
3'-Methoxy-4'-nitroflavone (0.05 μM; 0-30 h) induces aryl hydrocarbon receptor-dependent CYP1A1 mRNA expression in HaCaT cells, a process that requires FICZ present in commercial cell culture media[2].
3'-Methoxy-4'-nitroflavone (50 nM; 48 h) induces ethoxyresorufin O-deethylase activity in HaCaT cells only in the presence of 0.1 pM FICZ[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:MCF-10A human mammary epithelial cells
-
Concentration:0.1 nM, 1 nM, 10 nM, 100 nM, 1000 nM (co-treated with 10 nM TCDD)
-
Incubation Time:3 days
-
Result:Resulted in four times the number of apoptotic cells compared to TCDD alone at 100 nM.
Doubled the number of apoptotic cells compared to TCDD alone at 1000 nM.
-
Cell Line:MCF-10A human mammary epithelial cells
-
Concentration:0.1 nM, 1 nM, 10 nM, 100 nM, 1000 nM (co-treated with 10 nM TCDD); 0.1 nM, 1 nM, 10 nM, 100 nM, 1000 nM (treated alone)
-
Incubation Time:6 h
-
Result:Decreased TCDD-induced Akt serine phosphorylation at 1 nM.
Induced complete inhibition of TCDD-induced Akt serine phosphorylation at 100 nM.
Caused a slight increase in TCDD-induced Akt phosphorylation at 10 nM.
Had minimal effect on basal Akt phosphorylation when treated alone.\nInhibited TCDD-dependent Erk1,2 phosphorylation at 10 nM, 100 nM, and 1000 nM.
Significantly increased basal Erk1,2 activation alone at 1 nM.
-
Cell Line:MCF-10A human mammary epithelial cells
-
Concentration:0.1 nM, 1 nM, 10 nM, 100 nM (co-treated with 10 nM TCDD); 0.1 nM, 1 nM, 10 nM, 100 nM (treated alone)
-
Incubation Time:6 h
-
Result:Completely reversed the TCDD-induced 2-fold increase in TGFα mRNA at concentrations as low as 1 nM.
Increased TGFα mRNA over basal levels alone at 0.1 nM.
-
Cell Line:HaCaT cells
-
Concentration:0.05 μM
-
Incubation Time:0, 10, 20 and 30 h
-
Result:Significantly induced CYP1A1 mRNA expression in cells cultured in commercial DMEM, with no significant induction observed in cells cultured in DMEM with recrystallized tryptophan.
Chemical Information
-
CAS No. 145370-39-4
-
Molecular Weight 297.26
-
Formula C16H11NO5
-
SMILES
O=C1C=C(C2=CC(OC)=C([N+]([O-])=O)C=C2)OC3=C1C=CC=C3
-
Synonyms
MNF
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Collagen-Induced Arthritis
Collagen-induced arthritis (CIA) is an autoimmune murine model of rheumatoid arthritis in which immunization with type II collagen (CII) emulsified in an adjuvant induces a T cell- and autoantibody-driven inflammatory arthritis characterized by synovial hyperplasia, immune cell infiltration, and joint destruction. The model typically relies on genetically susceptible mouse strains (e. g. , DBA/1) and reproduces key features of human rheumatoid arthritis, including anti-collagen immune responses and progressive joint inflammation. Disease onset generally occurs within ~3-4 weeks after immunization, depending on antigen/adjuvant combinations and protocol variation. The immunopathology is driven by adaptive immune activation against CII, leading to systemic and local joint inflammation mediated by pro-inflammatory cytokines and effector immune cells, making CIA a standard preclinical platform for evaluating immunomodulatory and anti-arthritic interventions.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
DSS-Induced Colitis
Dextran sulfate sodium (DSS)-induced colitis is generated by administering DSS in mouse drinking water, producing epithelial injury, barrier disruption, weight loss, diarrhea, fecal blood, colon shortening, histologic mucosal damage, and inflammatory mediator changes; the model is mainly used to study acute or chronic intestinal inflammation resembling selected features of ulcerative colitis. DSS injury is interpreted through clinical and tissue readouts rather than a single molecular endpoint: daily body weight, stool consistency, and bleeding are combined into a disease activity index, while colon length, histology, cytokines, myeloperoxidase activity, intestinal permeability, and tight-junction markers provide complementary measures of inflammation and barrier damage.
-
TNBS-Induced Colitis
TNBS-induced colitis is produced by intrarectal delivery of 2,4,6-trinitrobenzene sulfonic acid in ethanol, where ethanol disrupts the mucosal barrier and TNBS haptenates colonic proteins, generating immune-mediated colonic inflammation with weight loss, diarrhea, ulceration, transmural injury, inflammatory-cell infiltration, and cytokine responses. The model is used as an experimental intestinal inflammation model with Crohn’s disease–like features, especially when Th1-type responses, IL-12–dependent inflammation, chronic relapsing inflammation, or fibrosis-related endpoints are studied.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
Purity & Documentation
References
[1]. Davis JW Jr, et al. The aryl hydrocarbon receptor antagonist, 3'methoxy-4'nitroflavone, attenuates 2,3,7,8-tetrachlorodibenzo-p-dioxin-dependent regulation of growth factor signaling and apoptosis in the MCF-10A cell line. Toxicol Appl Pharmacol. 2003;188(1):42-49. [Content Brief]
[2]. Wincent E, et al. Inhibition of cytochrome P4501-dependent clearance of the endogenous agonist FICZ as a mechanism for activation of the aryl hydrocarbon receptor. Proc Natl Acad Sci U S A. 2012;109(12):4479-4484. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)